The company's Q2 revenues came in above previously reported preliminary revenues of $835 million, but fell short of the analysts' estimate of $866.2 million.
The company's diagnostics segment's revenues were up 6 percent, while its discovery and analytical solutions segment's revenues grew less than 1 percent.
Danaher's life sciences revenues grew 6 percent, while its diagnostics revenues rose nearly 5 percent, including an increase of more than 20 percent at Cepheid.
The firm said that its molecular diagnostics sales growth in the quarter was negatively impacted by non-governmental organization purchasing patterns in Africa.
The firm said its growth was driven in part by increasing sales volumes of its gastrointestinal PancraGen business and endocrine ThyGeNext/ThyraMir business.
The publisher of the Science family of journals will allow some authors to place peer-reviewed versions of their papers into publicly accessible repositories.